

Karyopharm Therapeutics Inc.
Form 10-Q/A
December 23, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

Amendment No. 1

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2013

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number: 001-36167

Karyopharm Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

26-3931704

(I.R.S. Employer
Identification Number)

2 Mercer Road

Natick, MA

(Address of principal executive offices)

01760

(Zip Code)

(508) 975-4820

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer
(Do not check if a
smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of December 16, 2013, there were 29,749,593 shares of Common Stock, \$0.0001 par value per share, outstanding.

Explanatory Note

The purpose of this Amendment No. 1 on Form 10-Q/A to Karyopharm Therapeutic Inc.'s quarterly report on Form 10-Q for the quarter ended September 30, 2013, filed with the Securities and Exchange Commission on December 20, 2013 (the "Form 10-Q"), is solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T.

No other changes have been made to the Form 10-Q. This Amendment No. 1 speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date and does not modify or update in any way disclosures made in the original Form 10-Q.

Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

Item 6. Exhibits.

The exhibits filed as part of this Quarterly Report on Form 10-Q/A are set forth on the Exhibit Index hereto, which Exhibit Index is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: December 23, 2013

KARYOPHARM THERAPEUTICS INC.

By: /s/ PAUL BRANNELLY

Paul Brannelly
Senior Vice President, Finance & Administration
(Principal financial and accounting officer)

EXHIBIT INDEX

| Exhibit Number | Description of Exhibit | Incorporated by Reference | | | Exhibit Number | Filed Herewith |
|----------------|---|---------------------------|-------------|----------------|----------------|----------------|
| | | Form | File Number | Date of Filing | | |
| 3.1 | Restated Certificate of Incorporation | 8-K | | | | |
| 3.2 | Amended and Restated By-Laws | 8-K | | | | |
| 10.1 | 2013 Stock Incentive Plan | S-1/A | 333-191584 | 10/28/13 | 10.3 | |
| 10.2 | Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan | S-1/A | 333-191584 | 10/28/13 | 10.4 | |
| 10.3 | Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan | S-1/A | 333-191584 | 10/28/13 | 10.5 | |
| 10.4 | 2013 Employee Stock Purchase Plan | S-1/A | 333-191584 | 10/28/13 | 10.6 | |
| 31.1 | Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended. | 10-Q | 001-36167 | 12/20/13 | 31.1 | |
| 31.2 | Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended. | 10-Q | 001-36167 | 12/20/13 | 31.2 | |
| 32.1 | Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | 10-Q | 001-36167 | 12/20/13 | 32.1 | |
| 32.2 | Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | 10-Q | 001-36167 | 12/20/13 | 32.2 | |
| 101.INS | XBRL Instance Document* | | | | | X |
| 101.SCH | XBRL Taxonomy Extension Schema Document* | | | | | X |
| 101.CAL | XBRL Taxonomy Calculation Linkbase Document* | | | | | X |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document* | | | | | X |
| 101.LAB | XBRL Taxonomy Label Linkbase Document* | | | | | X |

* Submitted electronically herewith

